Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, metastatic, non-squamous, non-small cell lung cancer (NSCLC) despite immune checkpoint inhibitor (ICI) treatment, in Q2 2026 Company plans to submit a

#CADL Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

www.stocktitan.net/news/CADL/candel-therape...

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation Oncology (ASTRO) 2025 meeting, demonstrating improved prostate cancer-specific disease-free survival (DFS), independent of radiation therapy modality utilized

#CADL Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

www.stocktitan.net/news/CADL/candel-therape...

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer PHOENIX, Oct. 14, 2025/ PRNewswire/-- Trinity Capital Inc., a leading alternative asset manager, today announced the commitment of $130 million in growth capital to Candel Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer. Candel Therapeutics is developing a clinical...

#TRIN #CADL Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer

www.stocktitan.net/news/TRIN/trinity-capita...

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc. $50 million drawn down at closing, with access to up to an additional $80 million Strengthens Company’s financial position; enables initiation of phase 3 clinical trial of CAN-2409 in non-small cell lung cancer (NSCLC) Provides non-dilutive capital and additional financial flexibility ahead of a

#CADL Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

www.stocktitan.net/news/CADL/candel-therape...

Adaptive Deception Framework Boosts Cybersecurity with AI‑Driven Detection

The new CADL adaptive deception framework detects network attacks with a 99.88% detection rate and only 0.13% false positives on the CICIDS2017 benchmark. getnews.me/adaptive-deception-frame... #cadl #cybersecurity #ai

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025 CAN-2409 improved disease-free survival in patients with intermediate-to-high-risk, localized prostate cancer compared to placebo in patients treated with either conventional or moderate hypofractionated radiotherapy with curative intent, independent of the specific modality of radiation therapy

#CADL Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

www.stocktitan.net/news/CADL/candel-therape...

Leading Indicators, Wednesday September 3, 2025 – Crystal Equity Research

Small-cap stocks gapping down in trading, Wed Sept 3rd - #FLYYQ #CJET #ERAS #CADL #SKLZ - More: crystalequityresearch.com/leading-indi... - #smallcap

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights Presented positive results from the phase 3 randomized, placebo-controlled clinical trial of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer, during an oral presentation at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO) Received FDA Regenerative

#CADL Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

www.stocktitan.net/news/CADL/candel-therape...

Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer Candel Therapeutics (Nasdaq: CADL) has received European Medicines Agency (EMA) Orphan Designation for its CAN-2409 treatment for pancreatic cancer. This adds to existing FDA Orphan Drug and Fast Track Designations received in 2024 and 2023.The company's phase 2a clinical trial demonstrated remarkable results, with median overall survival of 31.4 months in the CAN-2409 plus standard of care arm versus 12.5 months in the control arm. Notably, three of seven treated patients were still alive at data cut-off with survival of 66.0, 63.6, and 35.8 months.CAN-2409 is an investigational immunotherapy that delivers the HSV-tk gene to tumor cells, potentially inducing systemic immune responses against multiple therapy-resistant solid tumors. The EMA designation provides benefits including reduced fees, protocol assistance, and up to 10 years of market exclusivity if approved.

#CADL Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer

www.stocktitan.net/news/CADL/candel-therape...

Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution Candel Therapeutics (Nasdaq: CADL), a clinical-stage biopharmaceutical company, has expanded its presence in Russell indexes following the 2025 Russell US Indexes reconstitution. The company was added to multiple value-oriented indexes including the Russell 2500 Value®, Russell Small Cap Value®, Russell 2000 Value®, Russell Microcap Value®, and Russell 3000E® Value Index, while maintaining its position in the Russell 3000® Index.This expansion comes at a crucial time as Candel prepares for a potential Biologics License Application for CAN-2409 in intermediate-to-high-risk localized prostate cancer. The company continues to advance its multimodal immunotherapy platform across various solid tumors, focusing on developing biological immunotherapies for cancer treatment.

#CADL Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution

www.stocktitan.net/news/CADL/candel-therape...

Laser beam targeting a cancer cell in a digital medical visualization, representing advanced cancer treatment technology developed by Candel Therapeutics.

#CADL is picking up momentum. H.C. Wainwright issued a Buy rating with a $23 PT following strong Phase 3 prostate cancer data, while Zacks upgraded the stock to Strong Buy on improving earnings estimates.
#CandelTherapeutics
prismmarketview.com/candel-thera...

Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, has agreed to sell approximately 3.2 million

#CADL Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

www.stocktitan.net/news/CADL/candel-therape...

Digital illustration of a cancer cell targeted by immune cells, symbolizing precision oncology, with a focus on Candel Therapeutics.

Breakthrough alert! #CandelTx
( #CADL) earns FDA Breakthrough Therapy Designation for CAN-2409, a game-changing prostate cancer treatment. Promising trial data shows improved survival rates.
Read more: prismmarketview.com/candel-wins-...

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer Candel Therapeutics (NASDAQ: CADL) has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for CAN-2409, its biological immunotherapy candidate for treating newly diagnosed localized prostate cancer. The designation, based on positive phase 3 trial results, could expedite development and review processes. The trial met its primary endpoint with significant improvements: - 30% reduction in prostate cancer recurrence or death risk - 38% improvement in prostate-specific disease-free survival - 80.4% pathological complete response vs 63.6% in control - 67.1% of patients achieved PSA nadir

#CADL Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

www.stocktitan.net/news/CADL/candel-therape...

研修会参加しました
とても学びが多い時間を皆さんと共有できました
有り難うございました
#高室成幸先生　#CADL

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025 Candel Therapeutics (NASDAQ: CADL) announced positive Phase 3 results for CAN-2409 in localized prostate cancer treatment, to be presented at ASCO 2025. The trial met its primary and secondary endpoints, showing a 30% reduction in cancer recurrence or death risk. CAN-2409, combined with valacyclovir and standard radiation therapy, demonstrated statistically significant improvement in disease-free survival (p=0.0155) compared to placebo. Key findings include: 80.4% pathological complete responses vs 63.6% in control, significant increase in PSA nadir achievement (67.1% vs 58.6%), and a favorable safety profile with low treatment-related adverse events (1.7%). This marks the first successful Phase 3 trial in localized prostate cancer in over 20 years, with Candel planning to submit a Biologics License Application in Q4 2026.

#CADL Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

www.stocktitan.net/news/CADL/candel-therape...

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights Candel Therapeutics (NASDAQ: CADL) reported Q1 2025 financial results and significant clinical progress. The company's lead candidate CAN-2409 showed positive Phase 3 results in prostate cancer, with BLA submission planned for Q4 2026. Notable achievements include: • Promising survival data in pancreatic cancer (PDAC), with median overall survival of 31.4 months vs 12.5 months in control group • Strong results in non-small cell lung cancer (NSCLC), with 24.5-month median overall survival in ICI-inadequate responders • Favorable Phase 1b results in high-grade glioma Financial highlights: Q1 2025 showed net income of $7.4 million compared to $8.2 million loss in Q1 2024. Cash position of $92.2 million expected to fund operations into Q1 2027. R&D expenses were $4.0 million, while G&A expenses reached $4.1 million.

#CADL Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

www.stocktitan.net/news/CADL/candel-therape...

Major Phase 3 Trial Results: Breakthrough Prostate Cancer Treatment Data to be Revealed at ASCO 2025 Groundbreaking Phase 3 data for innovative prostate cancer therapy CAN-2409 combines with radiation treatment. Johns Hopkins CEO to present full efficacy results.

#CADL Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

www.stocktitan.net/news/CADL/candel-therape...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with declining money flow, Wed Apr 16th - #WNW #TRST #QRHC #WTI #SHCO #NVRO #MAX #KLC #FRGE #DTC #ZD #VREX #SCLX #ADVM #CADL #DOYU #GREE #IMTX #KIDS #PDLB - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Breakthrough Prostate Cancer Drug Shows 30% Better Results as Candel Secures Key Partnership Strategic partnership with IDEA Pharma accelerates commercialization of CAN-2409, following impressive Phase 3 prostate cancer trial showing 30% reduction in disease recurrence.

#CADL Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

www.stocktitan.net/news/CADL/candel-therape...

Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights Candel Therapeutics (NASDAQ: CADL) reported its Q4 and full year 2024 financial results, highlighting significant clinical progress across its pipeline. The company announced positive phase 3 data for CAN-2409 in prostate cancer, showing a 30% reduction in cancer recurrence risk and 80.4% pathological complete responses. In pancreatic cancer, CAN-2409 demonstrated notable survival improvements, with median overall survival of 31.4 months versus 12.5 months in the control group.Financial highlights include:Q4 2024 R&D expenses: $4.8M (vs $7.3M in Q4 2023)Q4 2024 net loss: $14.1M (vs $11.1M in Q4 2023)Cash position: $102.7M as of December 31, 2024Runway extended into Q1 2027Key upcoming milestones include final overall survival data for CAN-2409 in NSCLC (Q1 2025) and biomarker data for CAN-3110 in high-grade glioma (Q4 2025). The company plans to submit a BLA for CAN-2409 in prostate cancer in Q4 2026.

#CADL Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

www.stocktitan.net/news/CADL/candel-therape...

One easy and tangible way to combat food insecurity in your community is by helping to stock local micropantries. Thank you to the #CADL for being such a good host! #CADLCares

Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer Candel Therapeutics (NASDAQ: CADL) has announced positive final survival data from its Phase 2 clinical trial of CAN-2409 in non-metastatic pancreatic cancer. The randomized controlled study showed a remarkable improvement in estimated median overall survival - 31.4 months in the CAN-2409 treatment group versus only 12.5 months in the control group for patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC).Notably, three of seven patients treated with CAN-2409 were still alive at 66.0, 63.6, and 35.8 months after enrollment, with survival from diagnosis reaching 73.5, 68.8, and 41.3 months respectively. This survival duration significantly exceeds expectations for standard pancreatic cancer treatment.CAN-2409, a first-in-class multimodal immunotherapy designed for in situ vaccination against the patient's tumor, demonstrated a favorable safety profile and has previously received both Fast Track Designation and Orphan Drug Designation from the FDA for PDAC treatment. Based on these promising results, Candel plans to prepare for a larger, late-stage randomized controlled clinical trial of CAN-2409 in PDAC.

#CADL Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

www.stocktitan.net/news/CADL/candel-therape...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume gains, Thu Feb 20th - #ANIX #VS #SABR #AMPL #CADL #FGEN #INSG #LUNG #NEGG #OESX #CYD #ENFN #HLF #MD #XYF #RCB #TIF #PRPH #TCRX #XOS - More: crystalequityresearch.com/SmCpStr/ - #smallcap

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#RIOT, #GME, #SANA, #CADL, #PINS

#OptionFlow #OptionsTrading #Trading

Candel Therapeutics' Cancer Drug Shows Remarkable 30% Reduction in Prostate Cancer Recurrence Breakthrough phase 3 data reveals CAN-2409's success in prostate cancer treatment, while showing promising pancreatic cancer survival rates of 28.8 months vs 12.5 control.

#CADL Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025

www.stocktitan.net/news/CADL/candel-therape...

Oof #CADL that's rough. I hope not to see you back at 5.04. $CADL

Candel Therapeutics Announces Pricing of Public Offering Candel Therapeutics (CADL) has announced the pricing of a public offering, consisting of 10,000,001 shares of common stock at $6.00 per share and pre-funded warrants to purchase 3,333,333 shares at $5.99 per warrant. The offering is expected to generate approximately $80 million in gross proceeds and close around December 16, 2024. The company has granted underwriters a 30-day option to purchase up to 2,000,000 additional shares. Proceeds will fund product development, including preparation for a Biologics License Application for CAN-2409 in prostate cancer, and general corporate purposes. The offering is led by joint bookrunning managers Citigroup, BofA Securities, and Canaccord Genuity.

#CADL Candel Therapeutics Announces Pricing of Public Offering

www.stocktitan.net/news/CADL/candel-therape...